Building sustainable healthcare
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check for the health industry. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. We have customers in more than 25 countries in the healthcare and medical research sectors. Our technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology.
Milestones
2013
The company was founded based on scientific innovation: a blood test that can detect a wide variety of molecules from a single sample.
Read more about Nightingale Health's technology.
2015
Our blood analysis technology was, and still is, widely used by world-leading scientists making novel findings in the field of chronic diseases.
Browse the list of publications.
2017
We obtained our first regulatory approvals, paving the way for healthcare use. Our quality management system was certified and we received a CE marking for the blood analysis technology.
2018
We kicked off a multi-year collaboration with the world’s largest biobank: UK Biobank.
Additionally, we won multiple awards including Health Innovation of the Year, Finnish Startup of the Year, and Best Health Tech Startup of the Year.
Read more about our collaboration with UK Biobank.
2019
We expanded to the United States by setting up a laboratory in Pittsburgh, Pennsylvania in collaboration with our shareholder PerkinElmer Inc.
Additionally, we became a private healthcare service provider and launched a pilot of our first direct-to-consumer service in Finland.
2020
We expanded to Japan in collaboration with our shareholder Mitsui & Co, Ltd. As part of the expansion, we set up an office and laboratory in the heart of Tokyo.
2021
Our Series B shares were listed on the Nasdaq Helsinki First North Growth Market, and we raised EUR 110 million in new funding to grow the company.
Visit our investor pages.
2022
We launched the direct-to-consumer service Livit by Nightingale Health which utilizes at-home blood collection.
Additionally, we announced our expansion into genetics and launched an international center of excellence for genomic data analysis.
Read our latest news.
2023
We announced an agreement with Suomen Terveystalo Oy to adopt Nightingale Health's technology in nationwide occupational healthcare in Finland.
Additionally, we rolled out a remote blood collection kit for our medical research and clinical trial customers, and announced a collaboration with Innoquest Diagnostics.
2024
We announced collaborations with Kaiser Foundation, ZOE, Boston Heart Diagnostics, 23andMe, and Phenome Health. We also acquired all intellectual property assets of the Velvet blood collection device and secured our position as the sole provider of a fully integrated remote health check.
Additionally, our new laboratory in the UK started operating, and we also announced that we will open a new laboratory in the United States. In addition, we completed the analysis of blood samples from all 500,000 UK Biobank.
Read our latest news.
Management team & founders
Teemu Suna
Chief Executive Officer, Founder
Antti Kangas
Chief Technology Officer, Founder
Satu Saksman
Chief Operating Officer
Minja Salmio
Chief Legal Officer
Tuukka Paavola
Chief Financial Officer
Salla Ruosaari, PhD
Chief R&D Officer
Jeffrey Barrett, PhD, FMedSci
Chief Scientific Officer
Pasi Soininen, PhD
Laboratory Director, Founder
Peter Würtz, PhD
Scientific Director, Founder
Board of directors
- Antti Kangas
- Olli Karhi, MD
- Ilkka Laurila
- Leena Niemistö, MD, PhD
- Timo Soininen
- Teemu Suna
Scientific advisory board
- Prof. John Danesh
- Prof. José Ordovás
- Prof. Eline Slagboom
- Prof. George Davey Smith
Nightingale Health Group
Finland
Nightingale Health Plc
HQ & Laboratory
Mannerheimintie 164a, 00300 Helsinki, Finland
Laboratory
Neulaniementie 2, 70210 Kuopio, Finland
Estonia
Nightingale Health Estonia OÜ
Harju maakond,
Tallinn,
Kesklinna linnaosa,
Rotermanni tn 14, 10111
Germany
Nightingale Health Germany GmbH
Kolonnenstraße 8,
10827 Berlin
Japan
Nightingale Health Japan KK
Welltus Inc
Office & Laboratory
Uchikanda Mid Square 1F
Uchikanda 1-16-8, Chiyoda-ku
Tokyo 101-0047
Singapore
Nightingale Health Asia Pte. Ltd.
77 Robinson Road
#13 - 00 Robinson 77
Singapore 068896
Sweden
NG Health Sweden AB
Kungsgatan 56,
111 22 Stockholm
United Kingdom
Nightingale Health UK Limited
5 New Street Square
EC4A 3TW London
United States
Nightingale Health United States, Inc.
6325 Main Street, Suite 100,
Williamsville, NY 14221